Chikungunya vaccine candidate Phase 3 trial: Induced neutralizing antibody titers in 98.5% of subjects after a single vaccination

Specialty vaccine company, Valneva, announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough Designation status by the Food and Drug Administration (FDA). The trial, involving 4,115 adults, aged 18 years and above, across 44 sites in the U.S., met its primary endpoint inducing [...]

The post Chikungunya vaccine candidate Phase 3 trial: Induced neutralizing antibody titers in 98.5% of subjects after a single vaccination appeared first on Outbreak News Today.